Andrey Ignatenko

Andrey counsels clients in various sectors, with a particular focus on pharmaceutical, medical devices, and life sciences industries, on their corporate transactions, as well as advising on related antitrust and regulatory compliance matters.

In addition to his transactional practice, Andrey has more than a decade of experience in US, EU, and UK sanctions and export control matters concerning Russia, Belarus, and certain other countries. He has assisted clients in conducting internal investigations and resolving enforcement actions, as well as with preparation and implementation of compliance programs.

As part of his pro bono efforts, Andrey has provided legal assistance to a number of charities and other nonprofits on governance and compliance matters.

Before joining Morgan Lewis, Andrey was a paralegal in the corporate practice of another international law firm. He is fluent in Russian and English.

M&A, Divestitures, Joint Ventures

• A few prominent Western companies on the divestment or wind-down of their Russian businesses
• Trillium Flow Technologies, a portfolio company of private equity firm First Reserve, in its acquisition of Termomeccanica Pompe, a supplier of related spare parts as well as the related maintenance and after-sales services
• A global manufacturing company on the restructuring of its Russian subsidiary and related compliance, corporate, and commercial matters
• A private equity investment firm in connection with the consolidation of its telecom tower business with one of Russia’s largest telecommunications companies, including advice on JV arrangements
• Pioneer Capital Invest, a Kazakh investment company, on the acquisition of 100% shares of JSC Asian-Pacific Bank from the Central Bank of the Russian Federation (Bank of Russia), including support with legal due diligence, transaction documentation and regulatory filings
• The Russia-China Investment Fund (RCIF) on the establishment and joint development of pharmaceutical holding company Binnopharm Group, one of the three largest pharmaceutical manufacturers in Russia
• Comtech Telecommunications Corp. in the acquisition of UHP Networks Inc., a provider of innovative and disruptive satellite ground station technology solutions
• A leading producer of green chemistry products in connection with its exit from a joint venture with one of the leading Russian companies in the pulp and paper industry
• Yandex, a leading tech company in Russia, on acquisition by the ride-hailing and food-delivery JV with Uber of the call centers and cargo business of Vezet Group
• A private US medical device company focused on the development of hyperspectral imaging solutions on its exit from a joint venture with a foreign venture capital fund
• A leading Russian pharmaceutical company in connection with its strategic partnership with a leading medical equipment manufacturer in respect of manufacturing and distribution of diagnostic imaging systems in Russia and the Commonwealth of Independent States (CIS)
• A subsidiary of a Russian high-technology pharmaceutical company in connection with a strategic partnership with the largest manufacturer of scientific instruments for the scientific industry over establishing local manufacturing of radio therapeutic equipment
• One of the largest private transportation and logistics holding companies in Russia that specializes in port logistics comprising marine terminals (grain, containers, port services, and other assets) on its acquisition through a public auction of 50% plus two shares in the largest Russian intermodal container operator that handles container cargo throughout Europe and Asia; this transaction has been recognized as the largest privatization deal in Russia in 2019
• A multinational health and personal care products company on the sale of its Russian distribution company, which sells a wide range of traditional and homeopathic over-the-counter pharmaceutical products, to a European buyer; in connection with the sale, the parties also entered into a long-term manufacturing and supply agreement
• A global financial services firm on the sale of a minority stake in a large Russian bank to principals of one of Russia’s largest private banks
• The mass media division of one of the world’s largest media conglomerates focused primarily on cinema and cable television on a joint venture (which broadcast and distributed more than 10 pay television channels in Russia) with a Russian company related to a prominent Russian business group
• A leading provider of global mobile satellite services on the sale of its Russian subsidiary
• A global manufacturing supply company on its acquisition of a privately held bearings company business in Russia
• A large US company on a joint venture with the Kazakhstani national railway company and a Russian partner to produce diesel engines in Kazakhstan

Antitrust & Regulatory Compliance

• An American private investment firm on a wide range of regulatory issues in connection with its $2.1 billion acquisition of a medical devices division of a leading pharmaceutical and medical devices company, including on reissuance of marketing authorizations for the whole portfolio of products in Russia
• A prominent US medical device company on promotion of its medical devices and consumables in Russia and local state procurement rules
• Heritage Capital on obtaining a merger clearance in Russia for the acquisition of a controlling interest in luxury travel company Abercrombie & Kent Group of Companies S.A., and a strategic partnership with Geoffrey J.W. Kent, its founder, chairman, and CEO
• A biopharmaceutical company on the localization of its product manufacturing
• A Russian high-technology pharmaceutical company on a variety of competition law and merger clearance issues in connection with its strategic partnership with a Japanese producer of medical systems, including assistance with preparation and negotiation of the distributorship agreement, joint venture agreement, technology license agreement, supply agreement for product kits, and other transaction documents
• A subsidiary of a Russian high-technology pharmaceutical company on Russian competition law issues in connection with a strategic partnership with the largest manufacturer of scientific instruments for the scientific industry over establishing local manufacturing of radio therapeutic equipment
• A global pharmaceutical company that develops and delivers life-transforming therapies for patients with rare, life-threatening diseases on market dominance and other applicable Russian competition law requirements in connection with the entry into a distributorship agreement with its local partner for commercialization of two brand new orphan drugs
• A consortium of sovereign investment funds on the merger control and foreign investments law aspects of its investment into the pharmaceutical holding created by a prominent Russian industrial group and a major Russian state-owned bank
• A European manufacturer of optical medical devices on obtaining necessary regulatory approvals for the distribution of its products in Russia, including approvals for clinical trials
• A global producer of high-tech specialty chemical products on Russian competition matters for the acquisition of a major developer and distributor of innovative chemical solutions for the agroscience, health, and nutrition science markets
• A leading global pharmaceutical company focused on specialist therapeutic areas of oncology, neurodegenerative diseases, fertility, endocrinology, cardiometabolic care, and general medicine products on a distribution and cooperation agreement with a Russian distributor
• A biopharmaceutical company on regulatory pathways for the approval of biosimilar products
• A global healthcare company manufacturing branded generic pharmaceuticals, medical devices, and nutrition products on anticounterfeiting issues in Russia and the strategic development of a trademark portfolio in Russia and the CIS
• A global biopharmaceutical company that develops and delivers life-transforming therapies for patients with rare, life-threatening diseases on regulatory matters, including the inclusion of certain of the company’s drugs on the Russian vital and essential drugs list
• A global pharmaceutical company specializing in brain diseases on a master license and distribution agreement with a Russian distributor, including counseling on marketing campaigns
• A global biopharmaceutical company on compliance with rules for pharmaceutical marketing and distribution in Russia involving samples, company visits, gifts, and entertainment
• An international television network on arrangements to cover the XXII Olympic Winter Games in Sochi